Literature DB >> 16904340

The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance.

Anja Fuchs1, Marco Colonna.   

Abstract

Natural killer (NK) cells have important functions in the innate immunity to tumors. Recognition of tumor cells by NK cells is mediated by the interaction of activating and inhibitory NK cell receptors with ligands expressed on the tumor target. In addition, NK cell-target cell interactions require the engagement of adhesion molecules that stabilize the cell-cell conjugate. Recently, several novel NK cell receptors have been reported to regulate NK cell adhesion and activation through interaction with ligands of the nectin and nectin-like (Necl) family of adhesion molecules. We here review current knowledge on these receptors, CD226, CD96 and CRTAM, and their role in tumor immunosurveillance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16904340     DOI: 10.1016/j.semcancer.2006.07.002

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  53 in total

1.  miR-30c-1* promotes natural killer cell cytotoxicity against human hepatoma cells by targeting the transcription factor HMBOX1.

Authors:  Jiuyu Gong; Rongrong Liu; Ran Zhuang; Yun Zhang; Liang Fang; Zhuwei Xu; Liang Jin; Tao Wang; Chaojun Song; Kun Yang; Yuying Wei; Angang Yang; Boquan Jin; Lihua Chen
Journal:  Cancer Sci       Date:  2012-02-13       Impact factor: 6.716

2.  The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions.

Authors:  Christopher J Chan; Ludovic Martinet; Susan Gilfillan; Fernando Souza-Fonseca-Guimaraes; Melvyn T Chow; Liam Town; David S Ritchie; Marco Colonna; Daniel M Andrews; Mark J Smyth
Journal:  Nat Immunol       Date:  2014-03-23       Impact factor: 25.606

3.  Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells.

Authors:  Giovanni F Torelli; Nadia Peragine; Sara Raponi; Daria Pagliara; Maria S De Propris; Antonella Vitale; Alice Bertaina; Walter Barberi; Lorenzo Moretta; Giuseppe Basso; Angela Santoni; Anna Guarini; Franco Locatelli; Robin Foà
Journal:  Haematologica       Date:  2014-03-21       Impact factor: 9.941

Review 4.  A novel interface consisting of homologous immunoglobulin superfamily members with multiple functions.

Authors:  Zhuwei Xu; Boquan Jin
Journal:  Cell Mol Immunol       Date:  2010-01       Impact factor: 11.530

Review 5.  Line of attack: NK cell specificity and integration of signals.

Authors:  Yenan T Bryceson; Eric O Long
Journal:  Curr Opin Immunol       Date:  2008-04-23       Impact factor: 7.486

6.  The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity.

Authors:  Noa Stanietsky; Hrvoje Simic; Jurica Arapovic; Amir Toporik; Ofer Levy; Amit Novik; Zurit Levine; Meirav Beiman; Liat Dassa; Hagit Achdout; Noam Stern-Ginossar; Pinhas Tsukerman; Stipan Jonjic; Ofer Mandelboim
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-07       Impact factor: 11.205

Review 7.  Nectin family of cell-adhesion molecules: structural and molecular aspects of function and specificity.

Authors:  Dibyendu Samanta; Steven C Almo
Journal:  Cell Mol Life Sci       Date:  2014-10-19       Impact factor: 9.261

8.  CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity.

Authors:  Amelia Roman Aguilera; Viviana P Lutzky; Deepak Mittal; Xian-Yang Li; Kimberley Stannard; Kazuyoshi Takeda; Günter Bernhardt; Michele W L Teng; William C Dougall; Mark J Smyth
Journal:  Oncoimmunology       Date:  2018-02-01       Impact factor: 8.110

9.  Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors.

Authors:  Yenan T Bryceson; Hans-Gustaf Ljunggren; Eric O Long
Journal:  Blood       Date:  2009-07-23       Impact factor: 22.113

10.  Increased levels of soluble CD226 in sera accompanied by decreased membrane CD226 expression on peripheral blood mononuclear cells from cancer patients.

Authors:  Zhuwei Xu; Tao Zhang; Ran Zhuang; Yun Zhang; Wei Jia; Chaojun Song; Kun Yang; Angang Yang; Boquan Jin
Journal:  BMC Immunol       Date:  2009-06-02       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.